Business Description
Andros Pharmaceuticals Co Ltd
ISIN : TW0006917008
Description
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.32 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.44 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.46 | |||||
| Beneish M-Score | -3.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -43.3 | |||||
| 3-Year EBITDA Growth Rate | -17.8 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | -6.6 | |||||
| 3-Year Book Growth Rate | 46.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.43 | |||||
| 9-Day RSI | 51.77 | |||||
| 14-Day RSI | 49.3 | |||||
| 6-1 Month Momentum % | -18.36 | |||||
| 12-1 Month Momentum % | -33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.16 | |||||
| Quick Ratio | 14.13 | |||||
| Cash Ratio | 13.84 | |||||
| Days Inventory | 794.54 | |||||
| Days Sales Outstanding | 997.67 | |||||
| Days Payable | 3.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.5 | |||||
| Shareholder Yield % | 0.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.88 | |||||
| Operating Margin % | -9156.52 | |||||
| Net Margin % | -8466.96 | |||||
| FCF Margin % | -5866.09 | |||||
| ROE % | -20.33 | |||||
| ROA % | -17.62 | |||||
| ROIC % | -95.51 | |||||
| ROC (Joel Greenblatt) % | -216.61 | |||||
| ROCE % | -18.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1023.81 | |||||
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 2.04 | |||||
| EV-to-EBIT | -8.09 | |||||
| EV-to-EBITDA | -8.89 | |||||
| EV-to-Revenue | 679.64 | |||||
| EV-to-FCF | -11.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.44 | |||||
| Price-to-Net-Cash | 2.5 | |||||
| Earnings Yield (Greenblatt) % | -12.37 | |||||
| FCF Yield % | -4.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Andros Pharmaceuticals Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 0.805 | ||
| EPS (TTM) (NT$) | -1.87 | ||
| Beta | 0 | ||
| Volatility % | 31.11 | ||
| 14-Day RSI | 49.3 | ||
| 14-Day ATR (NT$) | 0.64535 | ||
| 20-Day SMA (NT$) | 21.425 | ||
| 12-1 Month Momentum % | -33.33 | ||
| 52-Week Range (NT$) | 19.8 - 37.35466 | ||
| Shares Outstanding (Mil) | 44.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Andros Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Andros Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Andros Pharmaceuticals Co Ltd Frequently Asked Questions
What is Andros Pharmaceuticals Co Ltd(ROCO:6917)'s stock price today?
The current price of ROCO:6917 is NT$21.50. The 52 week high of ROCO:6917 is NT$37.35 and 52 week low is NT$19.80.
When is next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917)?
The next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917) is .
Does Andros Pharmaceuticals Co Ltd(ROCO:6917) pay dividends? If so, how much?
Andros Pharmaceuticals Co Ltd(ROCO:6917) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers